SF Fibrosis Conference, 2018
The role of the fibrotic stroma - barrier or support?
![San Fransisco from Marin Headlands San Fransisco from Marin Headlands](https://www.uib.no/sites/w3.uib.no/files/styles/content_main/public/media/sf_from_marin_highlands3.jpg?itok=ex4d9QN_×tamp=1579195073)
Foto/ill.:
San Fransisco from Marin Headlands
Hovedinnhold
SIU Fibrosis conference, June 7-8, 2018
San Francisco
Venue: Aldea conference centre, UCSF
Organizers: Donald Gullberg and Valerie Weaver
Business meeting SIU - Upcoming student exchanges
June 7th | Session 1a. Cell-ECM interactions - Chair: C. McCulloch (UoT) | Notes |
8.30 – 9.10 | 1. Donald Gullberg, University of Bergen Integrin α11β1 - a fibroblast protein with a role in fibrosis | |
9.15 – 9.55 | 2. Andrew Leask, University of Western Ontario Fibroblast-specific expression of CCN2 is required for activation of cancer asssociated-fibroblasts, angiogenesis and metastasis in a murine mode of melanoma | External |
10.00-10.20 | Coffee | |
Session 1b. Cell-ECM interactions - Chair: D. Gullberg (UiB, UCSF) | ||
10.20-11.00 | 3. Christopher McCulloch, University of Toronto Role of Flightless in Remodeling of the Fibrotic Stroma | |
11.05-11.45 | 4. Boris Hinz, University of Toronto Macrophage-Myofibroblast (Mis-) Communication | External |
11.50-12.30 | 5. Dean Sheppard, UCSF Targeting TGFbeta-activing integrins to treat tissue fibrosis and cancer | |
12.35-13.00 | Lunch | |
Session 2a. Tumor stroma associated fibrosis - Chair: V. Weaver (UCSF) | ||
13.00-13.40 | 6. Roya Navab, University of Toronto Desmoplasia is associated with poor prognosis and carcinoma-associated fibroblasts heterogeneity in non-small cell lung cancer | |
13.45-14.25 | 7. Valerie Weaver, UCSF Tumor stiffness and hypoxia | |
14.30-15.05 | 8. Neil Bhowmick, Cedars Sinail Medical Centre, Los Angeles The role of glutamine in fibroblastic activation and tumor progression | External |
15.10-15.25 | Coffee | |
Session 2b. Tumor stroma associated fibrosis - Chair: D. Sheppard (UCSF) | ||
15.25-16.05 | 9. Zena Werb, UCSF Tissue fibrosis and hypoxia in aggressive, basal-like breast cancers | |
16.10-16.50 | 10. Tushar Desai, Stanford Mapping Wnt signaling niches at cellular resolution in intact lung during IPF progression | External |
16.55-17.30 | Business meeting SIU - Upcoming student exchanges | |
19.00 | Dinner – for speakers and some other invited guests | |
June 8th | Session 3a. Mechanisms of fibrosis - Chair: B. Hinz (UoT) | |
8.30 - 9.10 | 11. Ari Molofsky, UCSF Mesenchymal - immune crosstalk at lymphocyte tissue niches | |
9.15 - 9.55 | 12. Yang Chen, MD Anderson Cancer Centre, Houston Fibrosis and Cancer Metastasis | External |
10.00-10.20 | Coffee | |
Session 3b. Mechanisms of fibrosis - Chair: R. Navab (UoT) | ||
10.20-10.50 | 13. Tien Peng, UCSF Stromal diversity and plasticity in the maintenance of organ function andfibrotic repair | |
10.55-11.30 | 14.Tammy Chang, UCSF The Role of Focal Adhesion Kinase in Hepatic Fibrogenesis | |
11.35-12.10 | 15. Ori Maller, UCSF A reciprocal interplay between tissue fibrosis and tumor immunity in breast cancer | |
12.15-13.00 | Lunch | |
Session 4. Emerging anti-fibrotic therapies - Chair: S. Porter (Fibrogen) | ||
13.00-13.40 | 16. Bernard Coulie, Pliant Therapeutics Developing target engagement and inhibition tools to de-risk the clinical development of a dual selective αvβ6/αvβ1 integrin inhibitor in IPF and otherfibrotic diseases | |
13.45-14.25 | 17. Eduard Gorina, Fibrogen Pamrevlumab vs placebo in patients with IPF. Results of a Phase 2 Clinical Trial | |
14.30-15.10 | 18. Kenneth E. Lipson, Fibrogen Activity and mechanism of pamrevlumab (anti-CTGF) in a mouse radiation-induced lung fibrosis model | |
15.15-15.35 | Coffee |
Financed: SIU